A Multi District Litigation has been requested for the consolidation of the Invokana lawsuits by Invokana lawyers as lawsuits continue to increase. A consolidation is requested to facilitate proceeding under one judge and jurisdiction.
The lawsuits against the manufacturer of the diabetes drug Invokana are alleging serious injuries after taking Invokana, including heart attack, kidney damage and a dangerous blood condition known as ketoacidosis. The lawsuits claim that Johnson & Johnson and its subsidiary Janssen failed to warn patients and doctors about the risks of taking Invokana.
Invokana lawyers filed a motion on September 20 asking the U.S. Judicial Panel on Multidistrict Litigation to consolidate Invokana lawsuits. The formation of an MDL would transfer all cases to a single judge and jurisdiction.
Invikana lawyers explained in the motion that the FDA had received many reports of kidney damage as a result of patients taking Invokana, which led the FDA to issue a stronger Invokana warning risk with a June 2016 label change. That warning was preceded by another label change in May 2015, alerting users to the risk of ketoacidosi. Ketoacidoasis can be a life-threatening condition that occurs when blood acids known as ketones reach dangerously high levels. Additional warnings were added to the label in August 2016, noting that fatal cases of ketoacidosis had been reported with Invokana use.
What Is Invokana?
Invokana is a diabetes drug in the SGLT2 inhibitor category. It regulate blood sugar levels by encouraging the body to eliminate extra glucose in urine.
Consolidation has been requested for the District Court of New Jersey in Trenton, where 36 of the Invokana lawsuits are already pending. All of those cases are before Judge Brian R. Martinotti, a federal judge the motion notes has extensive experience with complex litigation.
If you or a loved one has had a life threatening event due to Invokana call out Invokana Helpline today.